Sema4 Research
Sema4 is a patient-centered health intelligence company dedicated to advancing healthcare through data-driven insights. Our cutting-edge research is essential to this mission.
Our accomplished research team is led by Sema4’s Founder and CEO, Eric Schadt, Ph.D., a world-renowned expert on constructing predictive models of disease. We publish regularly in peer-reviewed, high-impact factor journals and collaborate extensively with health systems, clinicians, and pharmaceutical companies to deliver patient-centered, clinically relevant insights that drive precision medicine.
By the numbers
peer-reviewed research papers published since 2017
h-index score of our Founder and CEO, Eric Schadt, Ph.D.
Sema4’s
h-index score
PhDs and MDs currently employed at Sema4
large next generation sequencing (NGS) panels run
Dr. William Oh, Sema4’s Chief Medical Science Officer, discusses Sema4’s expansion of its disparities cancer care study to enable access to comprehensive genomic testing for patients with advanced cancer among underserved communities. The Research to Advance Precision Medicine and Health Equity in Oncology Treatment (REPRESENT) trial will create one of the most diverse clinocogenomic datasets to understand genetic drivers of cancer and help resolve racial, ethnic, and socioeconomic disparities within clinical trials, research, and therapeutics.
Our research
Sema4’s research concentrates on structuring multidimensional data collected from our advanced genomic tests and real-world data sources into clinical insights. We use this structured data and our proprietary technology platforms, including bioinformatic pipelines and integrative predictive modeling, to discover disease mechanisms and identify clinically actionable biomarkers, and create products that support patient care, from information-driven genomic tests to digital tools.
Much of our research is powered by Centrellis®, Sema4’s innovative health intelligence platform, which enables us to generate a more complete understanding of disease and wellness and deliver data-driven insights to our clinical collaborators to help drive better health decisions.
Since 2017, Sema4’s scientists have published more than 210 papers in peer-reviewed, high-impact factor journals. We also regularly present our research at national and international conferences. For examples, click here to review our abstracts from ASCO 2021. Our research focuses on five interlinked areas:





View our Publications
How can digital risk assessment tools combine artificial intelligence and real-world data to reduce morbidity and mortality in postpartum hemorrhage (PPH)?
View our latest Sema4 Research Highlight showcasing two publications in a special print issue of “Informatics for Sex- and Gender-Related Health” in the Journal of the American Medical Informatics Association (JAMIA) to learn how:
- Sema4 developed a novel PPH risk stratification tool using longitudinal real-world data and advanced machine learning algorithms
- Digital phenotyping algorithms identified potential clinical thresholds potentially indicative of increased PPH risk that are not currently used in standard clinical practice
- Digital risk prediction tools enable earlier PPH identification, prevention, and intervention to improve maternal health outcomes
Our People
Sema4’s Founder and CEO, Eric Schadt, Ph.D., is a world-renowned expert on constructing predictive models of disease that link molecular biology to physiology to enable clinical medicine. He has published more than 450 peer-reviewed papers in leading journals, with a publication citation or h-index of 137. In addition, Dr. Schadt has contributed to discoveries relating to the genetic basis of common human diseases, such as cancer, diabetes, obesity, and Alzheimer’s disease, and received many awards, including the Thomson Reuters World’s Most Influential Scientific Minds Award.
Our research team, led by Dr. Schadt, includes world leaders in data science, machine learning, network modeling, and genomics. We currently employ more than 160 Ph.D.-level scientists, in addition to physician-scientists and certified technicians. Our ongoing collaborations with scientists and clinicians in the Mount Sinai and other healthcare systems allow Sema4’s research to remain patient-centered and clinically relevant.
Our Partnerships
As a research partner, Sema4 can support a range of studies, from optimizing biomarker discovery to leveraging our biorepository services and accelerating clinical trial enrollment. We can bring a range of capabilities to partnerships, including:



We currently partner with numerous pharmaceutical companies, major health systems, research consortia, clinicians, and advocacy groups.